{"entity":{"id":"nct07321015","kind":"trial","name":"A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance","aka":["Fzp-MA-TNBC"],"tldr":"A phase 2 trial in triple-negative breast cancer, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting.","summary":"A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance is a phase 2, interventional study registered as NCT07321015 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 72 participants, started 2026-01-20 and due to reach its primary completion in 2027-11-30. Interventions recorded: Fluzoparib Monotherapy. Conditions listed: Platinum-sensitive; TNBC, Triple Negative Breast Cancer; BRCA1/2 Mutation or Not. Triple-negative eligibility wording from the registry: \"Histologically confirmed triple-negative breast cancer (TNBC; ER \\<1%, PR \\<1%, HER2-negative)\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07321015","url":"https://clinicaltrials.gov/study/NCT07321015"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07321015","phase":"2","setting":"An Exploratory Single-Arm Study of Maintenance Fluzoparib in Platinum-Sensitive, Advanced Triple-Negative Breast Cancer Patients With BRCA1/2 Mutation or Wild-Type BRCA","sponsor":"Tianjin Medical University Cancer Institute and Hospital","participation":[{"nct":"NCT07321015","source":"https://clinicaltrials.gov/study/NCT07321015","fetchedAt":"2026-10-07T16:55:39.854Z","studySha256":"d3b1db48649f42dc3f2c26703bdbca43023e2e22594bb8129e6fb7e54f76adbe","overallStatus":"RECRUITING","lastUpdatePosted":"2026-08-21","leadSponsor":"Tianjin Medical University Cancer Institute and Hospital","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":72,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2026-01-20","startedType":"actual","enrolled":72,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07321015/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}